Leibniz University of Hanover

About: Leibniz University of Hanover is a education organization based out in Hanover, Niedersachsen, Germany. It is known for research contribution in the topics: Finite element method & Population. The organization has 14283 authors who have published 29845 publications receiving 682152 citations.

Antioxidative constituents of Rosmarinus officinalis and Salvia officinalis. II : Isolation of carnosic acid and formation of other phenolic diterpenes

Abstract: The phenolic diterpene carnosic acid appears to be the main substance for general oxidation leading to artifacts with gamma- or delta-lactone structure in extracts of Rosmarinus officinalis and Salvia officinalis. Until now it was only possible to prepare carnosic acid by hydrogenolysis of carnosol. A semipreparative HPLC method has been developed isolating carnosic acid among other phenolic diterpenes. The separated substances were identified by 13C-nuclear magnetic resonance (NMR), 1H-NMR, mass and IR spectroscopy. Conversion of carnosic acid and carnosol to other phenolic diterpenes was investigated by HPLC.

Clonal growth in Ailanthus altissima on a natural site in West Virginia

Abstract: The exotic tree Ailanthus altissima is usually con- fined to open sites. As an exception, Ailanthus established in a densely closed forest in West Virginia, which was analyzed with the aim to elucidate possible pathways of persistence in forest succession of this light-demanding pioneer species. Demographic analysis revealed a seedling mortality of 100 %. Instead, the understory is populated by clonal ramets, ranging from one to more than 19 yr of age, with a mean of 5 yr. Growth averages only 0.11 m/yr, and height is correlated with age. This clonal growth contrasts with the performance of Ailanthus on open sites. The possible ecological benefits of establishing a ramet bank in a resource-poor habitat are con- sidered in terms of space occupation of a pioneer species.

Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.

Abstract: To evaluate the clinical benefit of the prophylactic use of urate oxidase in children with non-Hodgkin's lymphoma (NHL), we analyzed the incidence and complications of tumor lysis syndrome (TLS) in children with B-cell acute lymphoblastic leukemia (B-ALL) or stage III/IV Burkitt's lymphoma and a lactate dehydrogenase (LDH) level ≥500 U/l before and after the introduction of a protocol amendment to use urate oxidase for the prophylaxes of TLS. Data from 1791 children with NHL enrolled in the two subsequent multicenter studies NHL-BFM 90 and 95 were evaluated. The presence of the side effects TLS, anuria, sepsis, and other complications during the first 2 weeks after admission were registered. Until March 1996, no urate oxidase was used (period 1). From November 1997 all children with B-ALL or stage III and IV B-NHL and LDH ≥500 U/l should receive urate oxidase prophylactically (period 3). In between (period 2), urate oxidase was given in a minority of hospitals therapeutically. Initial chemotherapy was identical. Altogether, 78 children (4.4%) developed a TLS. Patients with B-ALL had the highest risk to develop a TLS (26.4%) followed by B-ALL/Burkitt's lymphoma and a LDH ≥500 U/l (14.9%). In period 1, 16.1% and 9.2% of the latter children developed a TLS or anuria, respectively, compared to 12.3% and 6.2% in period 3 (p=NS). The incidence of sepsis remained unchanged (5.0% vs 4.6%). In children with B-ALL the differences in the incidence of TLS and anuria between period 3 and period 1 were more pronounced, reaching significance for anuria (15.4% vs 3.8%, p=0.03). Our results suggest that patients with the highest risk to develop a TLS might benefit from the prophylactic use of urate oxidase.